Products & Services
Cellular Dynamics is collaborating with several pharmaceutical partners to develop and deploy a number of cell types derived from induced pluripotent stem (iPS) cells to aid drug discovery and toxicity testing. Currently CDI markets iCell Cardiomyocytes, human heart cells available in the high quality, quantity, and purity required within discovery research. The company additionally provides cardiac toxicity drug testing services, including GLP and non-GLP hERG channel electrophysiological assays as well as action potential screens using cardiomyocytes.
